These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 16115103

  • 1. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA.
    Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
    [Abstract] [Full Text] [Related]

  • 2. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 3. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M.
    J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
    [Abstract] [Full Text] [Related]

  • 4. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
    Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, Warnock DW, Cryptococcal Disease Active Surveillance Group.
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
    [Abstract] [Full Text] [Related]

  • 5. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method.
    López-Jodra O, Torres-Rodríguez JM, Méndez-Vásquez R, Ribas-Forcadell E, Morera-López Y, Baró-Tomás T, Alia-Aponte C.
    J Antimicrob Chemother; 2000 May; 45(5):645-9. PubMed ID: 10797087
    [Abstract] [Full Text] [Related]

  • 6. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care.
    Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U.
    J Antimicrob Chemother; 2003 Oct; 52(4):683-6. PubMed ID: 12951350
    [Abstract] [Full Text] [Related]

  • 7. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
    Aller AI, Claro R, Castro C, Serrano C, Colom MF, Martín-Mazuelos E.
    Chemotherapy; 2007 Oct; 53(4):300-5. PubMed ID: 17496416
    [Abstract] [Full Text] [Related]

  • 8. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [Abstract] [Full Text] [Related]

  • 9. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [Abstract] [Full Text] [Related]

  • 10. [Multisite evaluation of a colorimetric broth microdilution antifungal susceptibility testing].
    Yamane N, Igari J.
    Rinsho Byori; 1997 Feb; 45(2):190-9. PubMed ID: 9121005
    [Abstract] [Full Text] [Related]

  • 11. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [Abstract] [Full Text] [Related]

  • 12. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.
    Poon M, Cronin DC, Wormser GP, Bottone EJ.
    Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290
    [Abstract] [Full Text] [Related]

  • 13. Study of the susceptibility of yeast isolates of clinical interest to five antifungal agents using the E test.
    Linares MJ, Muñoz JF, Solís F, Rodríguez FC, Valero A, Casal M.
    Rev Esp Quimioter; 1998 Mar; 11(1):64-9. PubMed ID: 9795292
    [Abstract] [Full Text] [Related]

  • 14. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
    Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R.
    J Antimicrob Chemother; 2007 Aug; 60(2):312-6. PubMed ID: 17553813
    [Abstract] [Full Text] [Related]

  • 15. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
    Warnock DW, Johnson EM, Rogers TR.
    J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
    [Abstract] [Full Text] [Related]

  • 16. Comparison of broth dilution and semisolid agar dilution for in vitro susceptibility testing of Cryptococcus neoformans.
    Del Poeta M, Barchiesi F, Morbiducci V, Arzeni D, Marinucci G, Ancarani F, Scalise G.
    J Chemother; 1994 Jun; 6(3):173-6. PubMed ID: 7983499
    [Abstract] [Full Text] [Related]

  • 17. [Pulmonary cryptococcosis treated by combination therapy of fluconazole plus flucytosine].
    Tanaka K, Kohno S, Maesaki S, Mitsutake K, Miyazaki H, Miyazaki T, Tomono K, Kaku M, Koga H, Hara K.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31(12):1528-33. PubMed ID: 8121088
    [Abstract] [Full Text] [Related]

  • 18. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
    Bii CC, Makimura K, Abe S, Taguchi H, Mugasia OM, Revathi G, Wamae NC, Kamiya S.
    Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
    [Abstract] [Full Text] [Related]

  • 19. [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid].
    Fujita S.
    Rinsho Byori; 1996 Apr; 44(4):373-8. PubMed ID: 8847821
    [Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
    Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.